Related Experiment Video
Updated: Apr 20, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
What is the next generation therapeutic strategy for castration-resistant prostate cancer
Si-Meng Wen, Chang-Yi Quan, Ning Jiang
1Department of Urology, Second Hospital of Tianjin Medical University; Chawnshang Chang Sex Hormone Research Center, Tianjin Institute of Urology, Tianjin Medical University, Tianjin, China.
Abstract:
Prostate cancer (PCa) is one of the most common cancers in the world. Since androgen receptor (AR) signal plays key roles in the PCa progression, targeting androgens via the current androgen deprivation therapy (ADT) is the main therapeutic strategy for advanced PCa. However, most patients who receive ADT, including the second generation anti-androgens enzalutamide (also known as MDV3100) may finally develop the castration (or anti-androgen) resistance after 12-24 months treatment. In the manuscript by Asangani et al., the authors demonstrated that targeting the amino-terminal bromodomains of BRD4 could preferentially suppress human castration-resistant prostate cancer (CRPC) cell lines. While further studies are required to understand the full impact of their findings, the innovative approach provides a potential novel epigenetic approach for the concerted blockade of oncogenic drivers in CRPC.
Insights
Targeting BRD4’s amino-terminal bromodomains shows promise for treating castration-resistant prostate cancer (CRPC). This epigenetic approach may overcome resistance to current androgen deprivation therapies (ADT).
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Prostate cancer (PCa) is a prevalent malignancy globally.
- Androgen receptor (AR) signaling is crucial for PCa progression, making androgen deprivation therapy (ADT) a primary treatment for advanced stages.
- Resistance to ADT, including enzalutamide, develops in most patients within 12-24 months, leading to castration-resistant prostate cancer (CRPC).
Purpose of the Study:
- To investigate novel therapeutic strategies for CRPC.
- To explore the potential of targeting epigenetic regulators in CRPC.
- To evaluate the efficacy of targeting BRD4 in CRPC cell lines.
Main Methods:
- The study focused on targeting the amino-terminal bromodomains of BRD4.
- Experiments were conducted on human castration-resistant prostate cancer (CRPC) cell lines.
Main Results:
- Targeting BRD4’s amino-terminal bromodomains demonstrated preferential suppression of CRPC cell lines.
- This approach offers a potential new avenue for CRPC treatment.
Conclusions:
- Targeting BRD4 represents a novel epigenetic strategy for CRPC.
- This approach may offer a way to overcome resistance to existing therapies like ADT.
- Further research is needed to fully elucidate the impact and application of this finding.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...